Cargando…
A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).
For the first time in a clinical study oral Ifosfamide was used: 65 elderly or unfit patients with small cell lung cancer (SCLC) were treated as outpatients with fractionated oral Ifosfamide and Etoposide. Forty patients (62%) had extensive stage (ED) disease. The median age of the patients was 66 y...
Autores principales: | Cerny, T., Lind, M., Thatcher, N., Swindell, R., Stout, R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247041/ https://www.ncbi.nlm.nih.gov/pubmed/2548560 |
Ejemplares similares
-
Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989) -
A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.
por: Anderson, H., et al.
Publicado: (1993) -
Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.
por: Gogas, H., et al.
Publicado: (1997) -
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
por: Bleehen, N. M., et al.
Publicado: (1993) -
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
por: Bleehen, N. M., et al.
Publicado: (1993)